Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:77

Review

Dai, Julia^1,2  Belum, Viswanath R.¹  Wu, Shenhong^3,4  Sibaud, Vincent⁵  Lacouture, Mario E.¹ 

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, New York, NY 10021 USA

[2] Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA

[3] SUNY Stony Brook, Dept Med, Div Med Oncol, Stony Brook, NY 11794 USA

[4] Northport Vet Adm Med Ctr, Dept Med, Div Hematol & Oncol, Northport, NY USA

[5] Inst Univ Canc, Inst Claudius Regaud, Dept Dermatol, Toulouse Oncopole, Toulouse, France

关键词: cabozantinib;    depigmentation;    dyspigmentation;    hyperpigmentation;    hypopigmentation;    imatinib;    ipilimumab;    nivolumab;    pazopanib;    pembrolizumab;    pigmentary;    repigmentation;    sorafenib;    sunitinib;    vitiligo;   

DOI  :  10.1016/j.jaad.2017.06.044

来源: Elsevier

【 摘 要 】

Background: The discovery of signaling networks that drive oncogenic processes has led to the development of targeted anticancer agents. The burden of pigmentary adverse events from these drugs is unknown. Objective: To conduct a systematic review and meta-analysis of published clinical trials and determine the incidence and risk of development of targeted therapye-induced pigmentary changes. Methods: A comprehensive search was conducted to identify studies reporting targeted therapy-induced pigmentary changes. The incidence and relative risk were calculated. Case reports and series were reviewed to understand clinical characteristics. Results: A total of 8052 patients from 36 clinical trials were included. The calculated overall incidences of targeted cancer therapy-induced all-grade pigmentary changes in the skin and hair were 17.7% (95% confidence interval [CI], 11.9-25.4) and 21.5% (95% CI, 14.9-30.1), respectively. The relative risk of all-grade pigmentary changes of skin and hair were 93.7 (95% CI, 5.86-1497.164) and 20.1 (95% CI, 8.35-48.248). Across 53 case reports/series (N = 75 patients), epidermal growth factor receptor and breakpoint cluster region-abelson inhibitors were the most common offending agents. Limitations: Potential under-reporting and variability in oncologists reporting these events. Conclusion: There is a significant risk of development of pigmentary changes during treatment with targeted anticancer therapies. Appropriate counseling and management are critical to minimize psychosocial impairment and deterioration in quality of life.

【 授权许可】

Free